Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

Aman U. Buzdar; George R. Blumenschein; Terry L. Smith; Kimberly C. Powell; Gabriel N. Hortobagyi; Hwee Y. Yap; Frank C. Schell; Brian C. Barnes; Frederick C. Ames; Richard G. Martin; Evan M. Hersh

doi:10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

Aman U. Buzdar, George R. Blumenschein, Terry L. Smith, Kimberly C. Powell, Gabriel N. Hortobagyi, Hwee Y. Yap, Frank C. Schell, Brian C. Barnes, Frederick C. Ames, Richard G. Martin, Evan M. Hersh

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

Original language	English (US)
Pages (from-to)	384-389
Number of pages	6
Journal	Cancer
Volume	53
Issue number	3
DOIs	https://doi.org/10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G
State	Published - Feb 1 1984
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

Fingerprint

Dive into the research topics of 'Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial'. Together they form a unique fingerprint.

Cite this

Buzdar, A. U., Blumenschein, G. R., Smith, T. L., Powell, K. C., Hortobagyi, G. N., Yap, H. Y., Schell, F. C., Barnes, B. C., Ames, F. C., Martin, R. G., & Hersh, E. M. (1984). Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. Cancer, 53(3), 384-389. https://doi.org/10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. / Buzdar, Aman U.; Blumenschein, George R.; Smith, Terry L. et al.
In: Cancer, Vol. 53, No. 3, 01.02.1984, p. 384-389.

Research output: Contribution to journal › Article › peer-review

Buzdar, AU, Blumenschein, GR, Smith, TL, Powell, KC, Hortobagyi, GN, Yap, HY, Schell, FC, Barnes, BC, Ames, FC, Martin, RG & Hersh, EM 1984, 'Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial', Cancer, vol. 53, no. 3, pp. 384-389. https://doi.org/10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. Cancer. 1984 Feb 1;53(3):384-389. doi: 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

@article{30587b45ef9a40daa531f15e93e97061,

title = "Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial",

abstract = "Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.",

author = "Buzdar, {Aman U.} and Blumenschein, {George R.} and Smith, {Terry L.} and Powell, {Kimberly C.} and Hortobagyi, {Gabriel N.} and Yap, {Hwee Y.} and Schell, {Frank C.} and Barnes, {Brian C.} and Ames, {Frederick C.} and Martin, {Richard G.} and Hersh, {Evan M.}",

year = "1984",

month = feb,

day = "1",

doi = "10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G",

language = "English (US)",

volume = "53",

pages = "384--389",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

AU - Buzdar, Aman U.

AU - Blumenschein, George R.

AU - Smith, Terry L.

AU - Powell, Kimberly C.

AU - Hortobagyi, Gabriel N.

AU - Yap, Hwee Y.

AU - Schell, Frank C.

AU - Barnes, Brian C.

AU - Ames, Frederick C.

AU - Martin, Richard G.

AU - Hersh, Evan M.

PY - 1984/2/1

Y1 - 1984/2/1

N2 - Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

AB - Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

UR - http://www.scopus.com/inward/record.url?scp=0021359951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021359951&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

DO - 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

M3 - Article

C2 - 6362814

AN - SCOPUS:0021359951

SN - 0008-543X

VL - 53

SP - 384

EP - 389

JO - Cancer

JF - Cancer

IS - 3

ER -

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this